Category: GLP-1/GIP/Glucagon Triple Agonist Research Peptide

Description:
Reta 40mg is a high-dose research formulation of Retatrutide, the revolutionary triple receptor agonist acting on GLP-1, GIP, and Glucagon receptors. By activating these three key metabolic pathways simultaneously, Retatrutide is considered one of the most advanced investigational peptides for studies in severe obesity, insulin resistance, fatty liver, and complex metabolic disorders.

With 40mg per vial, Reta offers researchers a larger supply of this potent peptide, suitable for extended studies or projects requiring sustained dosing. Its unique mechanism promotes enhanced satiety, reduced appetite, fat oxidation, improved glucose control, and increased energy expenditure, making it a next-generation candidate in metabolic research.

Key Features:

• 30mg high-strength research vial

• Triple agonist action on GLP-1, GIP, and Glucagon receptors

• Advanced research focus: weight loss, type 2 diabetes, fatty liver, metabolic syndrome

• Longer half-life designed for weekly research protocols

• Double the volume of Reta 20mg, ideal for extended investigations

CAS Number: 2381089-83-2

Disclaimer:
Reta 30mg is provided for research purposes only. It is not a licensed medicine and is not for human consumption.